BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6117153)

  • 41. Motor unit control in movement disorders.
    Petajan JH
    Adv Neurol; 1983; 39():897-905. PubMed ID: 6229163
    [No Abstract]   [Full Text] [Related]  

  • 42. [Studies of a decussate inhibiting reflex in the region of the quadriceps femoris muscle in man].
    Klepel H; Rabending G
    Psychiatr Neurol Med Psychol (Leipz); 1970 Feb; 22(2):54-8. PubMed ID: 4251547
    [No Abstract]   [Full Text] [Related]  

  • 43. Foreword.
    De Vivo DC; Johnston MV
    Ann Neurol; 2003; 54 Suppl 6():S1-2. PubMed ID: 12891647
    [No Abstract]   [Full Text] [Related]  

  • 44. Collicular dysfunction in attention deficit hyperactivity disorder.
    Overton PG
    Med Hypotheses; 2008; 70(6):1121-7. PubMed ID: 18215471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unusual compulsive motor activity during treatment with clothiapine in a mentally retarded adolescent.
    Coppola G; Morelli E; Bravaccio C; Federico R; Gritti A
    Brain Dev; 2004 Sep; 26(6):409-11. PubMed ID: 15275706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 47. Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
    Lloyd KG; Worms P
    Adv Biochem Psychopharmacol; 1981; 29():59-67. PubMed ID: 6114626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visual-motor disorders and psychological features in minimal brain dysfunction children.
    Cakirpaloglu P; Radil T; Langmeier J; Matĕjcek Z
    Act Nerv Super (Praha); 1989 Jun; 31(2):155-6. PubMed ID: 2800968
    [No Abstract]   [Full Text] [Related]  

  • 49. Some possible neurological substrates in Attention Deficit Disorders.
    Bloomingdale LM; Gold MS; Davies R
    Acta Paedopsychiatr; 1983 May; 49(1-2):47-60. PubMed ID: 6136145
    [No Abstract]   [Full Text] [Related]  

  • 50. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder.
    Avale ME; Falzone TL; Gelman DM; Low MJ; Grandy DK; Rubinstein M
    Mol Psychiatry; 2004 Jul; 9(7):718-26. PubMed ID: 14699433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Myoclonic hyperkinesis induced by repeated administration of picrotoxin into rat neostriatum].
    Iakimovskiĭ AF
    Biull Eksp Biol Med; 1993 Jan; 115(1):7-9. PubMed ID: 8054587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence for neurotransmitter abnormalities related to seizure activity in the epileptic baboon.
    Killam EK; Killam KF
    Fed Proc; 1984 Jul; 43(10):2510-5. PubMed ID: 6145626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder.
    Kantak KM; Singh T; Kerstetter KA; Dembro KA; Mutebi MM; Harvey RC; Deschepper CF; Dwoskin LP
    Behav Neurosci; 2008 Apr; 122(2):340-57. PubMed ID: 18410173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurobiology of animal models of attention-deficit hyperactivity disorder.
    Russell VA
    J Neurosci Methods; 2007 Apr; 161(2):185-98. PubMed ID: 17275916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The endogenous opioid system in neurological disorders of the basal ganglia.
    Sandyk R
    Life Sci; 1985 Nov; 37(18):1655-63. PubMed ID: 2865665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comorbidity in attention deficit hyperactivity disorder].
    Artigas-Pallarés J
    Rev Neurol; 2003 Feb; 36 Suppl 1():S68-78. PubMed ID: 12599106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pathophysiology of movement disorders.
    Marsden CD
    Neurol Clin; 1984 Aug; 2(3):435-59. PubMed ID: 6241955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Basal ganglia and psychiatric disorders: an experimental validation].
    Féger J; Worbe Y; Galineau L; Tremblay L
    Ann Pharm Fr; 2009 Sep; 67(5):320-34. PubMed ID: 19695368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Iatrogenic causes of neurologic disorders: part 2. Drug-related dysfunctions.
    Buchanan DS
    Geriatrics; 1978 Sep; 33(9):47-52. PubMed ID: 28268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.